Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULMGet Rating) in a research note issued to investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Shares of NASDAQ:PULM opened at $3.47 on Monday. Pulmatrix has a twelve month low of $3.43 and a twelve month high of $20.80. The business has a fifty day moving average of $4.47 and a 200-day moving average of $5.07.

Pulmatrix (NASDAQ:PULMGet Rating) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.36) EPS for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.15. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.16 million. Pulmatrix had a negative return on equity of 42.29% and a negative net margin of 542.41%. As a group, research analysts forecast that Pulmatrix will post -6.04 earnings per share for the current year.

Institutional Trading of Pulmatrix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parallax Volatility Advisers L.P. acquired a new stake in Pulmatrix in the fourth quarter worth about $43,000. Renaissance Technologies LLC increased its position in Pulmatrix by 7.3% in the second quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,300 shares during the period. Citadel Advisors LLC bought a new position in Pulmatrix during the second quarter worth about $141,000. Finally, Murchinson Ltd. bought a new position in Pulmatrix during the fourth quarter worth about $44,000. 44.12% of the stock is currently owned by institutional investors and hedge funds.

About Pulmatrix

(Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Further Reading

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.